Related Experiment Video
Updated: Jan 4, 2026
08:04
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
3.3K
A Wish List for Drug Development in Pediatrics
1Department of Pharmacy, Saint Barnabas Medical Center, Livingston, New Jersey 07039; Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854.
Journal of Pharmaceutical Sciences
|November 3, 2019
Summary
Pediatric drug delivery faces challenges with unpalatable liquids and improper parenteral compounding. Collaboration between clinicians and developers is crucial for improving pediatric dosage forms and patient care.
Area of Science:
- Pediatric pharmacology
- Drug delivery systems
- Pharmaceutical development
Background:
- Despite advances in pediatric drug development and labeling, significant issues persist with existing dosage forms.
- Current challenges impact the safe and effective administration of medications to children in clinical practice.
Purpose of the Study:
- To highlight and summarize the practical challenges encountered by clinicians regarding pediatric dosage forms and drug delivery.
- To emphasize the need for improved pharmaceutical solutions tailored for pediatric patients.
Main Methods:
- This commentary synthesizes common problems observed in clinical practice.
- It draws upon the experiences of healthcare providers caring for pediatric populations.
Main Results:
- Issues include unpalatable liquid formulations and the inappropriate use of syringes for long-term parenteral medication storage.
- These problems affect both long-standing generic medications and newer drug products.
Conclusions:
- There is a critical need for better-designed dosage forms for pediatric use.
- Enhanced collaboration between pediatric clinicians and pharmaceutical developers is essential to address these unmet needs and improve medication safety and efficacy in children.
Related Concept Videos
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
209
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
209
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
181
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
181
01:26Drug Discovery: Overview
10.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.8K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
160
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
160
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
222
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
222
01:28Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K